Immorta Bio Adds EY Veteran Howard Brooks to Advisory Board as Clinical Translation Nears

  • Howard Brooks, former EY Health Sciences Partner, joins Immorta Bio's Strategic Advisory Board on February 3, 2026.
  • Brooks brings 30+ years of healthcare strategy and governance experience to support Immorta Bio's clinical translation efforts.
  • Immorta Bio is developing dual-platform approach combining senolytic immunotherapy (SenoVax™) and regenerative cellular rejuvenation (StemCellRevivify™).
  • Company targets aging biology as root cause for applications across oncology, organ failure, and neurological disorders.

This strategic hire comes as Immorta Bio advances toward clinical translation of its aging biology-focused therapies. The appointment reflects growing industry recognition that addressing fundamental aging processes could unlock broad therapeutic applications across multiple disease categories. Brooks' deep experience with enterprise transformation and capital formation suggests the company may be positioning itself for significant scale-up in the near term.

Clinical Translation Pace
How Brooks' strategic guidance will accelerate Immorta Bio's path to clinic-ready therapies.
Governance Strengthening
Whether this advisory appointment signals preparation for future capital formation or partnership discussions.
Market Positioning
The company's ability to differentiate its dual-platform approach in the competitive longevity science space.